title: Pre-administration of L-tryptophan improved ADR-induced early renal failure in mice.
abstract: OBJECTIVE
  The aim of this study was to determine the localization of the rate-limiting enzyme indoleamine 2, 3-dioxygenase (IDO) and its metabolite in mice kidneys after adriamycin (ADR)-induced renal failure. We also examined the effect of L-tryptophan (Trp) administration on this model.
  
  
  METHODS
  BALB/c mice were treated with 15 mg/kg ADR to induce renal failure. The change of IDO and L-kynurenine (Kyn) following ADR-induced renal failure was examined by immunostaining combined with hematoxylin and eosin (HE) and Periodic acid-Schiff (PAS) staining for morphological analysis, and the concentration of L-Kyn was measured by HPLC. The effect of L-Trp administration on ADR-induced renal failure was also investigated.
  
  
  RESULTS
  Time-dependent increase of IDO immunostaining was observed in tubular cells from Day 4 after ADR injection. It was found that mice fed with L-Trp had less chance of renal failure at four days after ADR injection than mice untreated with L-Trp, but not at seven days. Further, L-Trp treatment significantly suppressed an increased level of TNF-alpha mRNA, but not of TGF-beta and IL1-beta after renal injury.
  
  
  CONCLUSIONS
  Local IDO expression in tubules was induced markedly after ADR- induced renal failure. L-Trp administration can be effective in suppressing ADR-induced renal failure at an early stage.
authors: Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Japan.
authors: Yuko
authors: Y
authors: Arioka
authors: Yasuko
authors: Y
authors: Yamamoto
authors: Masato
authors: M
authors: Hoshi
authors: Keishi
authors: K
authors: Matsumoto
authors: Manabu
authors: M
authors: Takamatsu
authors: Akira
authors: A
authors: Hara
authors: Mitsuru
authors: M
authors: Seishima
authors: Kuniaki
authors: K
authors: Saito
mesh_terms: D000818:Animals; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D015536:Down-Regulation; D004317:Doxorubicin / Q000009:adverse effects; D004801:Eosine Yellowish-(YS) / Q000494:pharmacology; D006416:Hematoxylin / Q000494:pharmacology; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000494:pharmacology*; D007668:Kidney / Q000378:metabolism; D007737:Kynurenine / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010504:Periodic Acid / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051437:Renal Insufficiency / Q000188:drug therapy*; D012545:Schiff Bases / Q000494:pharmacology; D013997:Time Factors; D014364:Tryptophan / Q000008:administration & dosage*
chemical_list: D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D012333:RNA, Messenger; D012545:Schiff Bases; D010504:Periodic Acid; D007737:Kynurenine; D004317:Doxorubicin; D014364:Tryptophan; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin